160 related articles for article (PubMed ID: 32234492)
21. Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.
Bianchini F; Portioli E; Ferlenghi F; Vacondio F; Andreucci E; Biagioni A; Ruzzolini J; Peppicelli S; Lulli M; Calorini L; Battistini L; Zanardi F; Sartori A
Cancer Lett; 2019 Apr; 446():25-37. PubMed ID: 30639534
[TBL] [Abstract][Full Text] [Related]
22. Identification of the interaction network of hub genes for melanoma treated with vemurafenib based on microarray data.
Quan L; Wang Y; Liang J; Shi J; Zhang Y; Tao K
Tumori; 2015; 101(4):368-74. PubMed ID: 25983087
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of LINC00691 promotes the proliferation and invasion of gastric cancer cells via the Janus kinase/signal transducer and activator of transcription signalling pathway.
Liang W; Xia B; He C; Zhai G; Li M; Zhou J
Int J Biochem Cell Biol; 2020 Jun; 123():105751. PubMed ID: 32330554
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of the paired box gene 3 inhibits the progression of skin cutaneous melanoma by inhibiting c-MET tyrosine kinase : PAX3 downregulation inhibits melanoma progression.
Zhang K; Yu C; Tian R; Zhang W; Tang S; Wang G
Mol Biol Rep; 2022 Oct; 49(10):9137-9145. PubMed ID: 36057879
[TBL] [Abstract][Full Text] [Related]
25. The nucleosome remodeling and deacetylase complex has prognostic significance and associates with immune microenvironment in skin cutaneous melanoma.
Liu X; Wang J
Int Immunopharmacol; 2020 Nov; 88():106887. PubMed ID: 32799111
[TBL] [Abstract][Full Text] [Related]
26. Identification of Therapeutic Targets and Prognostic Biomarkers Among Integrin Subunits in the Skin Cutaneous Melanoma Microenvironment.
Nurzat Y; Su W; Min P; Li K; Xu H; Zhang Y
Front Oncol; 2021; 11():751875. PubMed ID: 34660316
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA-365 Inhibits Cell Growth and Promotes Apoptosis in Melanoma by Targeting BCL2 and Cyclin D1 (CCND1).
Zhu Y; Wen X; Zhao P
Med Sci Monit; 2018 Jun; 24():3679-3692. PubMed ID: 29858490
[TBL] [Abstract][Full Text] [Related]
28. Sphingosine metabolism as a therapeutic target in cutaneous melanoma.
Dany M
Transl Res; 2017 Jul; 185():1-12. PubMed ID: 28528915
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting IL11RA to mitigate hepatic metastasis in skin cutaneous melanoma: Comprehensive insights from in vitro and in vivo investigations.
Zhang ZG; Zhu HM; Hua HK
Skin Res Technol; 2024 Mar; 30(3):e13618. PubMed ID: 38468436
[TBL] [Abstract][Full Text] [Related]
30. Systematic expression analysis of EAF family reveals the importance of EAF2 in melanoma.
Han W; Shen GL
Int Immunopharmacol; 2020 Nov; 88():106958. PubMed ID: 33182068
[TBL] [Abstract][Full Text] [Related]
31. Identification of CD38 as a potential biomarker in skin cutaneous melanoma using bioinformatics analysis.
Wang X; Wang P; Ge L; Wang J; Naqvi SMAS; Hu S
Oncol Lett; 2020 Oct; 20(4):12. PubMed ID: 32774485
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of key genes of the JAK-STAT signaling pathway in patients with cutaneous melanoma.
Pan F; Wang Q; Li S; Huang R; Wang X; Liao X; Mo H; Zhang L; Zhou X
Oncol Lett; 2020 Mar; 19(3):1928-1946. PubMed ID: 32194688
[TBL] [Abstract][Full Text] [Related]
33. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
34. Novel compounds TAD-1822-7-F2 and F5 inhibited HeLa cells growth through the JAK/Stat signaling pathway.
Yang T; Shi X; Kang Y; Zhu M; Fan M; Zhang D; Zhang Y
Biomed Pharmacother; 2018 Jul; 103():118-126. PubMed ID: 29649626
[TBL] [Abstract][Full Text] [Related]
35. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
36. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature.
Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R
Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598
[TBL] [Abstract][Full Text] [Related]
37. Tumoricidal effects of the JAK inhibitor Ruxolitinib (INC424) on hepatocellular carcinoma in vitro.
Wilson GS; Tian A; Hebbard L; Duan W; George J; Li X; Qiao L
Cancer Lett; 2013 Dec; 341(2):224-30. PubMed ID: 23941832
[TBL] [Abstract][Full Text] [Related]
38. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
[TBL] [Abstract][Full Text] [Related]
39. DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma.
Xue W; Zhu H; Liu H; He H
Front Oncol; 2022; 12():799185. PubMed ID: 35651810
[TBL] [Abstract][Full Text] [Related]
40. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
